Heterogeneity of KRAS Mutation Status in Rectal Cancer.

Anti-EGFR targeted therapy is of increasing importance in advanced colorectal cancer and prior KRAS mutation testing is mandatory for therapy. However, at which occasions this should be performed is still under debate. We aimed to assess in patients with locally advanced rectal cancer whether there...

Full description

Bibliographic Details
Published in:PLoS ONE
Main Authors: Peter Jo, Alexander König, Markus Schirmer, Julia Kitz, Lena-Christin Conradi, Azadeh Azizian, Markus Bernhardt, Hendrik A Wolff, Marian Grade, Michael Ghadimi, Philipp Ströbel, Hans-Ulrich Schildhaus, Jochen Gaedcke
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Online Access:http://europepmc.org/articles/PMC4827807?pdf=render

Internet

http://europepmc.org/articles/PMC4827807?pdf=render

Similar Items